I'd agree with a Complete Buy out is premature plus the...

I'd agree with a Complete Buy out is premature plus the offerings are quite diverse between SNT 5505 Myelofibrosis and SNT 9465 Scar Treatment.

BUT I do see the opportunity for either an early Equity Position to be taken in the entire Company or a Licensing Deal on SNT 5505 obviously on gaining further approvals..

If you look at the recent climb in value for DXB ,,, 41c base SP price announced a licensing deal and ran to 75c and that was single Territory / Region not a global licensing deal.

My personal view is SNT is currently undervalued,,, yes I know its easy to say but the run up to 9c seemed value attributing plus the last two positive data announcements have been followed swiftly with Capital Raisings..

So if we base the current true value benchmarked at 9c which is an MC of circa $150m , then you apply a simple 30% gain on positive data SNT should come in around $200m circa 12c a share..

Then if you apply Commercial Interest , which Gary has indicated "There are two parties interested in the Technology"
Now if one of those parties is a Fortune 500 SNT could lower their entry into ownership as we will benefit from the amplification of a large Resourced firm with Global Reach and customers in place including Governments and the largest Health Insurers and a sales force of over 5000..

My interest here originally was SNT 6302 which has morphed into 9465 which now looks to be an "At Home Application" where as SNT 6302 was clinic based application. 6302 looked to be burns focused (as it would be under Fiona Wood) now toward scaring and what I believe is a great commercial move toward surgical scars as it's amazingly there is no standard of care ' take home pack from surgery"

Any licensing deal will obviously come with an upfront payment ( Hurt Money so BP dont just shelve it and have to actually promote and forward the Treatment) that in itself creates and gains intense market awareness for the Company..

@kpax will have a greater understanding of the Myelofibrosis Market... But I can tell you now if SNT whisper this to market "1 cent gain" as the chatter and noise in the market currently is deafening ,,SNT will go unnoticed and not even be heard...

SNT don't seem to have signalled they are going all the way to Phase III mainly due to cost and time but upon positive Phase III deals come with a $B not an $M at the end of them ,,

SNT are about to enter one of Biotechs largest Catalysts and Inflection Points ,, Positive Phase II Data...... and I have an empty slot in the garage that needs filling ,,, NZT

"Ohhh plus we have Parkinsons Data from the UK Pending " might need a bigger garage .......